---
slug: cognitive-stack-adderall-insomnia
title: Semax, DSIP, and Selank: Evidence Review on Mechanisms Related to Cognition, Sleep, and Anxiety
canonical: https://miscsubjects.com/a/cognitive-stack-adderall-insomnia
---

## Overview

Data on Semax, DSIP, and Selank derive primarily from preclinical models, small human trials (often Russian-language or limited sample size), and mechanistic studies. No human trials examine the combination in Adderall (amphetamine) users or for stimulant-related insomnia, anxiety, or brain fog. Claims below are graded by evidence tier and separated by study type. No human data exist on long-term effects, interactions with stimulants, or use for cognitive concerns in this population.

## Semax

Semax is described as upregulating BDNF for neuroprotection and cognitive recovery (mechanistic).

### Human Data
- Small pilot studies in healthy volunteers reported changes in fMRI signals and attention/short-term memory measures (human, small n).
- Stroke patient studies noted increased plasma BDNF levels after courses of Semax (human, n~110 in one report).

### Preclinical Data
- Rat hippocampal studies showed Semax increased BDNF protein, trkB phosphorylation, and mRNA levels, correlating with improved conditioned avoidance responses (preclinical).

No human data on Semax for anxiety reduction or in stimulant users.

## DSIP

DSIP is described as promoting natural deep sleep without Ambien-class hangover effects (mechanistic).

### Human Data
- Open-label study (n=7 severe insomnia) reported normalized sleep in 6/7 cases for 3-7 months follow-up (human).
- Double-blind study (n=16 chronic insomniacs) found higher sleep efficiency and shorter latency vs placebo (human).
- Earlier small volunteer studies noted increased sleep time and efficiency (human, n<10).

All human trials had very small samples; mixed or modest results noted in reviews. No human data on DSIP with stimulants or for anxiety/brain fog.

### Preclinical Data
- Animal models of insomnia showed reduced wakefulness time with DSIP (preclinical).

## Selank

Selank is described as reducing anxiety via non-benzodiazepine pathways without sedation or addiction (mechanistic).

### Human Data
- Studies in generalized anxiety disorder (GAD) patients reported anxiolytic effects comparable to benzodiazepines, with some cognitive enhancement noted and no sedation/dependence in short-term use (human, small n, Russian trials; one n=30 comparison).
- GAD approval in Russia based on such data; rapid vs gradual responders observed in EEG/clinical scales (human, n=20).

### Preclinical Data
- Animal models demonstrated anxiolytic activity without typical benzodiazepine side effects (preclinical).

No human data on Selank for sleep or in Adderall users. Limited Western large-scale RCTs.

## Combination and Novelty

Limited commercial blends and user reports mention Semax+Selank+DSIP together for focus, calm, and sleep (anecdotal). No published human trials on the stack, interactions with amphetamines, or repair-vs-suppression outcomes in any population. All claims on combined use remain speculative.

## Sources and Limitations

Evidence is graded above. No large-scale, placebo-controlled Western trials exist for these peptides in the described context. Preclinical data predominate for mechanisms; human data are sparse and often small-scale.

---

Related:
[cognitive stack intro](/a/cognitive-stack-intro) · [dsip adderall insomnia](/a/dsip-adderall-insomnia)

[[embed:cognitive-stack-intro]]

[[embed:dsip-adderall-insomnia]]
